{"nctId":"NCT01645111","briefTitle":"An Open-label Trial of Clevidipine for Controlled Hypotension During Spinal Fusion","startDateStruct":{"date":"2012-06"},"conditions":["Neuromuscular Scoliosis"],"count":50,"armGroups":[{"label":"Clevidipine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Clevidipine"]}],"interventions":[{"name":"Clevidipine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Spinal fusion for neuromuscular scoliosis.\n\nExclusion Criteria:\n\n* Allergy to dihydropyridine calcium channel antagonists\n* Allergy to soy or eggs\n* Non-neuromuscular causes of scoliosis\n* Disorders of lipid metabolism (clevidipine is in a lipid base)","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Achieve Target MAP","description":"The time between start of clevidipine infusion and patient reaching target mean arterial pressure (MAP) at 55-65 mmHg","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":"11.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":50},"commonTop":[]}}}